Skip to main content

Summary

for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started

Description

Summary

Chromosomal analysis or the study of genetic differences in patients previously untreated with AML, ALL, MDS or MM may be helpful in the diagnosis and classification of disease. It may also improve the ability to predict the course of disease and the selection of therapy. Institutions must have either an Alliance-approved cytogeneticist or an agreement from an Alliance-approved main member cytogenetics laboratory to enroll a patient on CALGB 8461. The Alliance Approved Institutional Cytogeneticists list is posted on the Alliance for Clinical Trials in Oncology website.

Official Title

Cytogenetic Studies in Acute Leukemia and Multiple Myeloma: Companion to CALGB Treatment Studies For Previously Untreated Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS) or Multiple Myeloma (MM) Patients

Keywords

Acute Leukemia Acute Lymphoblastic Leukemia Myelodysplastic Syndrome Multiple Myeloma

Eligibility

For people ages 18 years and up

  1. Patients from adjuncts are eligible if the Main Member Cytogenetics laboratory has agreed to process samples from that adjunct.
  2. Within one month of registration on CALGB 8461, register onto a CALGB treatment study for previously untreated AML, ALL, MDS, or MM patients.
  3. Simultaneously with registration on CALGB 8461, register patients within the continental United States onto CALGB 9665 (LTB).

Locations

  • Camino Medical Group - Treatment Center
    Mountain View, California, 94040, United States
  • University Medical Center of Southern Nevada
    Las Vegas, Nevada, 89102, United States
  • CCOP - Nevada Cancer Research Foundation
    Las Vegas, Nevada, 89106, United States
  • Sunrise Hospital and Medical Center
    Las Vegas, Nevada, 89109, United States

Details

Status
in progress, not accepting new patients
Start Date
Sponsor
Alliance for Clinical Trials in Oncology
ID
NCT00048958
Lead Scientist
Lloyd Damon
Study Type
Observational
Last Updated
August 1, 2017